Compare AVXL & AVNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | AVNW |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 278.2M |
| IPO Year | 2013 | 2007 |
| Metric | AVXL | AVNW |
|---|---|---|
| Price | $2.52 | $21.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $22.00 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.3M | 149.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.29 |
| Revenue | N/A | ★ $243,858,000.00 |
| Revenue This Year | N/A | $5.59 |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | ★ N/A | $74.14 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $2.41 | $13.92 |
| 52 Week High | $13.99 | $27.02 |
| Indicator | AVXL | AVNW |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 59.71 |
| Support Level | $2.41 | $20.76 |
| Resistance Level | $2.80 | $22.95 |
| Average True Range (ATR) | 0.16 | 1.09 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 26.67 | 59.27 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.